UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

October 22, 2007

 

GENZYME CORPORATION

(Exact name of registrant as specified in its charter)

 

 

500 Kendall Street, Cambridge, Massachusetts  02142

(Address of Principal Executive Offices)  (Zip Code)

 

Registrant’s telephone number, including area code:

(617) 252-7500

 

		Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2. below):

 

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01   Other Events.

 

On October 22, 2007, Genzyme Corporation announced that the stockholders of Bioenvision, Inc. voted to approve the merger of Wichita Bio Corporation, a wholly-owned subsidiary of Genzyme, with and into Bioenvision. The merger was effective as of 12:01AM EST on October 23, 2007. A copy of the press release is included as Exhibit 99.1 hereto.

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	GENZYME CORPORATION
Dated: October 22, 2007	By:	/s/ Peter Wirth
		Peter Wirth
		Executive Vice President and
		Chief Legal Officer

 

3

 

Item 9.01		Financial Statements and Exhibits.
(c)		Exhibits
99.1		Press Release of Genzyme Corporation dated October 22, 2007.

 

4